Pulmonx Corp
(STU:4NI)
€
6.8
0.05 (0.74%)
Market Cap: 272.17 Mil
Enterprise Value: 224.02 Mil
PE Ratio: 0
PB Ratio: 3.09
GF Score: 59/100 Pulmonx Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022 / 08:40PM GMT
Release Date Price:
€20.2
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst
Good afternoon, and welcome to the second day -- nearly the end of the second day of the Morgan Stanley Healthcare Conference. I am Cecilia Furlong, medical device analyst here at Morgan Stanley. It is my pleasure to have Pulmonx with us; CEO, Glen French; CFO, Derrick Sung. Thank you both for being here today.
Glendon E. French
Pulmonx Corporation - CEO, President & Director
Thank you.
Questions & Answers
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst
And I think we've started a lot of these conversations with macro. I'd love to start with CONVERT given what we've heard recently from a data standpoint. But as you think about just for the field? What's the greatest potential benefit as you contemplate further adoption?
Glendon E. French;Cecilia E. Furlong
Pulmonx Corporation - CEO, President & Director
Specific to CONVERT or...
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot